SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Vila C.)
 

Sökning: WFRF:(Vila C.) > Long-Term Safety of...

  • Johannsson, Gudmundur,1960Gothenburg University,Göteborgs universitet,Institutionen för medicin,Institute of Medicine (författare)

Long-Term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients

  • Artikel/kapitelEngelska2022

Förlag, utgivningsår, omfång ...

  • 2022-04-03
  • The Endocrine Society,2022

Nummerbeteckningar

  • LIBRIS-ID:oai:gup.ub.gu.se/319033
  • https://gup.ub.gu.se/publication/319033URI
  • https://doi.org/10.1210/clinem/dgac199DOI

Kompletterande språkuppgifter

  • Språk:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Context Data on long-term safety of growth hormone (GH) replacement in adults with GH deficiency (GHD) are needed. Objective We aimed to evaluate the safety of GH in the full KIMS (Pfizer International Metabolic Database) cohort. Methods The worldwide, observational KIMS study included adults and adolescents with confirmed GHD. Patients were treated with GH (Genotropin [somatropin]; Pfizer, NY) and followed through routine clinical practice. Adverse events (AEs) and clinical characteristics (eg, lipid profile, glucose) were collected. Results A cohort of 15 809 GH-treated patients were analyzed (mean follow-up of 5.3 years). AEs were reported in 51.2% of patients (treatment-related in 18.8%). Crude AE rate was higher in patients who were older, had GHD due to pituitary/hypothalamic tumors, or adult-onset GHD. AE rate analysis adjusted for age, gender, etiology, and follow-up time showed no correlation with GH dose. A total of 606 deaths (3.8%) were reported (146 by neoplasms, 71 by cardiac/vascular disorders, 48 by cerebrovascular disorders). Overall, de novo cancer incidence was comparable to that in the general population (standard incidence ratio 0.92; 95% CI, 0.83-1.01). De novo cancer risk was significantly lower in patients with idiopathic/congenital GHD (0.64; 0.43-0.91), but similar in those with pituitary/hypothalamic tumors or other etiologies versus the general population. Neither adult-onset nor childhood-onset GHD was associated with increased de novo cancer risks. Neutral effects were observed in lipids/fasting blood glucose levels. Conclusion These final KIMS cohort data support the safety of long-term GH replacement in adults with GHD as prescribed in routine clinical practice.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Touraine, P. (författare)
  • Feldt-Rasmussen, U. (författare)
  • Pico, A. (författare)
  • Vila, G. (författare)
  • Mattsson, A. F. (författare)
  • Carlsson, M. (författare)
  • Korbonits, M. (författare)
  • van Beek, A. P. (författare)
  • Wajnrajch, M. P. (författare)
  • Gomez, R. (författare)
  • Yuen, K. C. J. (författare)
  • Göteborgs universitetInstitutionen för medicin (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical Endocrinology & Metabolism: The Endocrine Society107:7, s. 1906-19190021-972X1945-7197

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy